NDAORALCAPSULEPriority Review
Approved
Jan 1985
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
Priority Review
ZOVIRAX (acyclovir) by GSK is dna polymerase inhibitors [moa]. Approved for genital herpes, herpes simplex, herpes zoster and 1 more indications. First approved in 1985.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZOVIRAX (acyclovir) is an oral nucleoside analog that inhibits viral DNA polymerase to treat herpes simplex virus (HSV) and varicella-zoster virus (VZV) infections. It is indicated for genital herpes, herpes simplex, herpes zoster, and herpes labialis. The drug represents a foundational antiviral therapy with over 35 years of clinical use and established safety.
LOE Approaching
As a legacy product approaching LOE, the brand team is likely in transition or consolidation mode, with smaller commercial infrastructure compared to growth-stage products.
Mechanism of Action
DNA Polymerase Inhibitors
Indications (4)
Worked on ZOVIRAX at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.